Open AccessThe Fate of Intranasally Instilled Silver Nanoarchitectures
Author(s) -
Agata Zamborlin,
Maria Laura Ermini,
Maria Summa,
Giulia Gian,
Valentina Frusca,
Ana Katrina Mapanao,
Doriana Debellis,
Rosalia Bertorelli,
Valerio Voliani
Publication year - 2022
Publication title -
nano letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.853
H-Index - 488
eISSN - 1530-6992
pISSN - 1530-6984
DOI - 10.1021/acs.nanolett.2c01180
Subject(s) - nasal administration , nanotechnology , biodistribution , respiratory tract , biosafety , nanotoxicology , medicine , pharmacology , materials science , respiratory system , biology , nanoparticle , pathology , microbiology and biotechnology , in vivo
The intranasal administration of drugs allows an effective and noninvasive therapeutic action on the respiratory tract. In an era of rapidly increasing antimicrobial resistance, new approaches to the treatment of communicable diseases, especially lung infections, are urgently needed. Metal nanoparticles are recognized as a potential last-line defense, but limited data on the biosafety and nano/biointeractions preclude their use. Here, we quantitatively and qualitatively assess the fate and the potential risks associated with the exposure to a silver nanomaterial model (i.e., silver ultrasmall-in-nano architectures, AgNAs) after a single dose instillation. Our results highlight that the biodistribution profile and the nano/biointeractions are critically influenced by both the design of the nanomaterial and the chemical nature of the metal. Overall, our data suggest that the instillation of rationally engineered nanomaterials might be exploited to develop future treatments for (non)communicable diseases of the respiratory tract.